Featured news from NHIVNA
HIV-related news from NAM
Sofosbuvir/ledipasvir cures most previously treated hepatitis C patients with cirrhosis
Liz Highleyman, 2014-12-10 10:10:00
Difficult-to-treat hepatitis C patients with liver cirrhosis who were not cured with a prior course of first-generation HCV protease inhibitors had a sustained response rate of 96-97% when re-treated with sofosbuvir/ledipasvir with ribavirin for 12 weeks or without ribavirin for 24 weeks, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in Boston. Sofosbuvir/ledipasvir also worked well for people previously treated with other sofosbuvir-containing regimens.
The advent of interferon-free therapy combining direct-acting antiviral agents that target different steps of the hepatitis C virus (HCV) lifecycle has brought about a revolution in treatment. But the best approach for hard-to-treat patients - including people who did not respond to previous treatment and those with extensive liver damage - remains to be determined.
Source:1
